Cartesian Therapeutics, Inc. (RNAC) stock
Close on Nov 10, 2026Market cap $208.46MP/E –Yield –
Cartesian Therapeutics, Inc. reported revenue of $1.03M for the twelve months to Sep 30, 2026. Free cash flow was -$89.89M. At the latest close the market valued the company at $208.46M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $208.46M
- P/E ratio
- –
- Price to sales
- 203.38
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -43.12%
Fundamentals
- Revenue
- $1.03M
- Net income
- -$127.46M
- EPS, diluted
- -$4.94
- Free cash flow
- -$89.89M
- Book value per share
- -$4.30
- Diluted shares
- 30M
Trading
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Previous close
- $7.02
- Open
- $6.92
- Day's range
- $6.76 – $7.28
- Volume
- 94,864
- Average volume (20 days)
- 128,075
- Index membership
- Russell 2000 (since Jun 2023)
- Beta (5 years)
- 1.42
- 52-week range
- $5.60 – $11.00
- RSI (14 days)
- 50.4
- Volatility (1 year)
- 83.7%
- Relative volume
- 0.71×
- WACC
- 10.7%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 10, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNAC | S&P 500 | Difference | RNAC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.3% | -3.7% | +1.3 pts | ||
| 3 months | -21.3% | -2.7% | −18.6 pts | ||
| Year to date | -4.4% | +10.8% | −15.3 pts | ||
| 1 year | -4.8% | +11.2% | −16.1 pts | ||
| 3 years | -76.0% | +76.5% | −152.5 pts | -37.9% | +20.8% |
| 5 years | -93.8% | +72.9% | −166.8 pts | -42.7% | +11.6% |
| 10 years | -98.9% | +304.8% | −403.7 pts | -36.2% | +15.0% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cartesian Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Update
- Update
About Cartesian Therapeutics
Pharmaceutical Preparations
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that develops mRNA-engineered cell therapies for the treatment of autoimmune diseases. The company uses a proprietary platform to insert messenger RNA into cells, enabling outpatient administration without the need for pre-treatment chemotherapy or viral integration. Its lead product candidate is Descartes-08, an autologous chimeric antigen receptor T-cell therapy in clinical evaluation for conditions such as generalized myasthenia gravis and myositis. The company also developed Descartes-15 for multiple myeloma and explores in-vivo cell engineering technologies. Its primary target patients are individuals living with serious, chronic autoimmune disorders.
Company profile, executives and historyCartesian Therapeutics stock: common questions
What is Cartesian Therapeutics's stock price?
RNAC closed at $6.89 on Nov 10, 2026, down 1.85% on the day. Over the past 52 weeks it traded between $5.60 and $11.00.
What is Cartesian Therapeutics's market cap?
Cartesian Therapeutics was worth $208.46M at the close on Nov 10, 2026: the share price times the diluted shares outstanding.
What is RNAC's P/E ratio?
Cartesian Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.94), so it has no meaningful P/E ratio.
How much revenue does Cartesian Therapeutics make?
Cartesian Therapeutics reported revenue of $1.03M for the twelve months to Sep 30, 2026.
Does Cartesian Therapeutics pay a dividend?
No. Cartesian Therapeutics has not paid a cash dividend over the last twelve months.
When does Cartesian Therapeutics report earnings next?
Cartesian Therapeutics is expected to report Q4 FY2026 results on Mar 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RNAC stock performed over the past year?
Including dividends, RNAC returned -4.8% over the past year, against +11.2% for the S&P 500.
How many RNAC shares are sold short?
2M shares were sold short at the latest FINRA report, 14.30% of the float, or 16.5 days of average trading volume.
Who are Cartesian Therapeutics's competitors?
Companies most similar to Cartesian Therapeutics by business, industry and size include DNTH, LGVN, NWBO, ERNA, MCRB.
See a number that looks wrong?